HLB Co., Ltd.
Tracked across 1 events · 7 articles · First seen Sep 22, 2026 · Last active Sep 22, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., announced on September 22, 2026 that the U.S. United States — Food and Drug Administration granted conditional acceptance of LYRFIGTU as the brand name for…
Impact: HLB Co., Ltd. is the majority owner of Elevar Therapeutics and its KOSDAQ-listed shares are the main market exposure to this event. The brand-name milestone is positive for HLB, but its stock closed down 2.82 percent on the KOSDAQ on the announcement day.
Sep 22, 2026 · 7 articles
ERGEN INTELLIGENCE
Track HLB Co., Ltd. live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard